App-Quantinova.ai

CD320 Regulates Bone Marrow Angiogenesis in Multiple Myeloma Via HGF-ERK Axis

Lingling Shu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

Ayrton Bangolo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

OSA and Hematological Malignancy- a National Database Study

Sruthi Ramanan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Solid malignancies

N/A

Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

Natalie Boytsov - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A Rare Case of Spontaneous Tumor Lysis Syndrome As a Consequence of Forgone Treatment in Multiple Myeloma

Kathleen Humkey - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Solid malignancies

Cyclophosphamide

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Fabio Serpenti - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dental and Oral Health

Solid malignancies

Cyclophosphamide

Light Chain(AL) Cardiac Amyloidosis: A Real World Data on Therapy and Outcomes

Sandeep Abhijit Pattnaik - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Solid malignancies

Cyclophosphamide

Global Health Status Inadequately Captures Longitudinal Changes in Quality of Life in Patients Receiving Carfilzomib for Multiple Myeloma: Electronic Patient-Reported Outcomes (ePROs) from a Prospective Observational Study

Ajay Major - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Solid malignancies

carfilzomib Intravenous

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Methylprednisolone

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

Alfred Chung - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Pembrolizumab

Ex Vivo out-Competition of Leukemia Stem Cells By Healthy Hematopoietic Stem Cells for Autologous Transplantation from Leukemia Patients

John M. Perry - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

N/A

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia

Yiyun Wang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

daratumumab Intravenous

Physiologix™ Serum Replacement and NB-ROC™ T Cell Culture Media Combination Shows Enhanced T-Cell Transduction Efficiency for CAR-T Therapy

Asma Ayari - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Developing CD70-Targeted CAR-T Cells for the Treatment of Hematological and Solid Malignancies

Yuan Lu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Gamma Delta T Cells for Acute Myeloid Leukemia

Fiorela Natali Hernandez Tejada - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Zoledronic acid

Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Hematological and Solid Tumour Malignancies

Ioanna Lazana - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Erbitux

Higher-Dose Donor Derived Ex Vivo Expanded Natural Killer Cell Infusion Prior to Haploidentical Stem Cell Transplantation on Acute Myeloid Leukemia: Efficacy and Safety

Weida Wang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Interleukin

CRC-403: A Phase 1/2 Study of bbT369, a Dual CD79a and CD20 Targeting CAR T Cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Frederick L. Locke - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Ibrutinib

Role of Anakinra in the Management of Steroid Refractory High Grade Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after Anti-CD 19 CAR-T Cell Therapy, a Single Center Experience

Ulyana Dashkevych - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anakinra

Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma

William Wesson - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Axicabtagene ciloleucel

Filters

41730 Abstracts